<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>may be responsible, in part, for the delayed epithelial wound closurein diabetic rat corneas.Commercial Relationships: HAIJING SUN, None; Feng Wang,None; Ilham Bettahi, None; Fushin X. Yu, NoneSupport: R01 EY017960Program Number: 2566 Poster Board Number: D0366Presentation Time: 2:45 PM - 4:30 PMClinical Factors Can Predict the Outcome of AutologousCultivated Limbal Epithelial TransplantationAnupam Bagdi 1 , Sayan Basu 1 , Hasnat Ali 2 , Virender S. Sangwan 1 .1 <strong>Cornea</strong>, L V Prasad Eye Institute, Hyderabad, India; 2 Biostatisticsand Clinical Epidemiology, L V Prasad Eye Institute, Hyderabad,India.Purpose: It is difficult to prognosticate the outcome of stem cellbased therapy for ocular surface disease because the risk factorspredisposing to failure of surgery are not clearly known.To addressthis issue,this study aimed to identify the clinical Indicatorsassociated with failure of autologous cultivated limbal epithelialtransplantation for the treatment of Limbal Stem Cell Deficiency(LSCD).Methods: This retrospective study included 526 eyes of patientssuffering from unilateral LSCD following ocular surface burns whounderwent autologous ex-vivo cultivated limbal epithelialtransplantation between 2001 and 2011. This procedure involvedobtaining a one-clock hour wide limbal biopsy from the healthyfellow eye and cultivating the limbal epithelial cells on a deepithelisedhuman amniotic membrane graft for 10-14 days. Aconfluent epithelial sheet along with the amniotic membrane graftwas then transplanted onto the affected eye after clearing away thepathologic tissue covering the cornea. Post-operatively success oftransplantation was defined as a completely epithelized, avascularand clinically stable corneal surface. A multivariate analysis wasperformed using multiple logistic regression to analyze the strengthof association between the pre-operative, intra-operative and postoperativeclinical factors and recurrence of LSCD.Results: Of the 526 eyes, the ocular surface was successfullyrestored in 292 (55.5%) eyes at a mean follow-up of 1.4 years.Among all the pre-, intra- and post-operative clinical factors thatwere assessed: presence of symblepharon (OR=1.2, P< 0.001),previous ocular surgeries (OR= 1.3, P= 0.02), pediatric age group(OR=1.4, P= 0.04) and simultaneous keratoplasty (OR=3.2, P= 0.02)were found to be associated with greater chances of failure ofautologous cultivated limbal epithelial transplantation.Conclusions: Patients with extensive symblepharon, patientspreviously having undergone multiple ocular reconstructiveprocedures, children and patients requiring keratoplasty along withautologous limbal transplantation are at higher risk of recurrence ofLSCD and need to be counseled accordingly.Commercial Relationships: Anupam Bagdi, None; Sayan Basu,None; Hasnat Ali, None; Virender S. Sangwan, NoneSupport: Partnership grant from Champalimaud Foundation, Lisbon,Portugal; Hyderabad Eye Research Foundation, Hyderabad, India;Department of Biotechlonology, New Delhi, India(BT/01/COE/06/02/10)Program Number: 2567 Poster Board Number: D0367Presentation Time: 2:45 PM - 4:30 PMUtilizing contact lenses as carriers for human corneal limbalepithelial and induced pluripotent stem cellsNir Erdinest, Abraham Solomon. Ophthalmology, Hadassah HebrewUniv Med Ctr, Jerusalem, Israel.Purpose: To delineate the best technique for culturing and carryinghuman corneal limbal epithelial cells and induced pluripotent stem(iPS) cells on contact lenses (CLs) for the purpose of celltransplantation for limbal stem cell deficiency (LSCD).Methods: Limbal explant sections from corneoscleral rims,remaining from corneal transplantation, or induced pluripotent stem(iPS) cells were placed on the inner aspect of 5 types of CLs coatedwith or without 0.1% gelatin. The CLs used included lotrafilcon A(Air Optix Night & Day® Aqua), vifilcon A (Focus Monthly®),lotrafilcon A (Focus Night & Day® Aqua), etafilcon A (1-DayAcuvue®) and nelfilcon A (Focus Dailies®). Plastic culture platesand the human amniotic membrane were used, respectively, asgrowth platform controls for the CLs. Comparison between thegrowth patterns on the different CLs and the gelatin coating wasmade with regard to epithelial proliferation rate and epithelial cellmorphology utilizing light and electron microscopy.Results: All the growth platforms yield monolayers culture cells withuniform epithelial cell morphology. There were marked differencesin growth patterns between the different CLs. The explants placed onsilicone hydrogel CL lotrafilcon A (CIBA Vision Corporation,Duluth, GA, USA) showed the fastest proliferative and migratoryrates, with CLs covered with gelatin. Explants applied on lotrafilconA were tightly attached to it, and growth was detected first on day 4.Lotrafilcon A (Air Optix Night & Day® Aqua) reached 91.2±8.5%confluence by day 16±2, and Lotrafilcon A (Focus Night & Day®)reached 93.7±6.2% confluence by day 14±3. iPS cells which wereseeded on CLs were attached to lotrafilcon A by day 3. Cellsexamined under light microscopy were morphologically similar tocorneal epithelium grown on 6 wells culture plate and amnioticmembrane. Electron microscopy revealed cell-to-cell links andmultiple cell layers. Microvilli and cell projections were also evidentand most probably served as anchorage points on the CLs surface.Conclusions: Silicone hydrogel CL lotrafilcon A was advantageousover the other types of CLs for culturing and carrying corneal limbalepithelial and iPS cells. These CLs may be used as possible carriersfor cultured human ocular surface epithelial cell sheets as a part of acell therapy strategy in LSCD.Commercial Relationships: Nir Erdinest, None; AbrahamSolomon, NoneProgram Number: 2568 Poster Board Number: D0368Presentation Time: 2:45 PM - 4:30 PMLumican Is Required for Epithelium Migration during Healingof <strong>Cornea</strong>l Epithelium DebridementJianhua Zhang, Vivien J. Coulson-Thomas, Yong Yuan, OsamuYamanaka, Hongshan Liu, Winston W. Kao. Ophthalmology,University of Cincinnati, Cincinnati, OH.Purpose: Purpose: Lumican, a member of small leucine richproteoglycan (SLRP), is a matrikine besides serving as anextracellular matrix ECM component and regulator of collagenfibrillogenesis. Previous studies have shown that lumican promoteshealing of corneal epithelial debridement via enhanced epithelial cellproliferation. The current study attempts to determine whetherlumican plays an additional role in promoting corneal wound healingby enhancing epithelial cell migration.Methods: Methods: Adult lumican null (Lum-/-), hemizygous(Lum+/-) and wild type (Lum+/+) mice were anesthetized andsubjected to circumvent corneal epithelium debridement (2 mm indiameter) with Agerbrush®. <strong>Cornea</strong>s were isolated at differentintervals (0 through 6 h) and subjected to whole mount IF in order tocharacterize the epithelial cell migration by analyzing the expressionand localization of cytoskeletal and adherens components, e.g.,paxillin, etc. The role of lumican on stress fiber and filopodia©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>formation were confirmed in vitro using a scratched wound model ofcultured human telomerase-immortalized corneal epithelial (HTCE)cells.Results: Results: Whole mount staining with phalloidin revealed adecrease in the migrated corneal epithelial sheet in Lum-/- mice, from10 and 105 µm in Lum+/+ mice to 0 and 5 µm in Lum-/- mice after 1and 6 h, respectively. Immunofluorescence staining revealed highexpression levels of paxillin throughout the epithelium with densestaining at the wound edge in Lum+/+ mice, however, Lum-/- micepresented very low expression levels of paxilin and a subtle increasein paxilin expression was restricted to the immediate wound edge.Moreover, paxilin staining revealed cellular projections in epithelialcells at the wound edge which were polarized into the wounded areasolely in the Lum+/+ mice. The in vitro scratch wound assay ofHTCE cells revealed that the addition of solely lumican to cellsmaintained in basic medium (in the absence of growth factors)enhanced stress fiber formation with filopodia projected to thewounded area to the same extent as that observed in completemedium.Conclusions: Discussion: Our observation suggests that lumicanplays a critical role in promoting wound healing via both theenhancement of cell locomotion and proliferation. Further studies areneeded to determine the molecular and cellular mechanism by whichlumican promotes wound healing.Commercial Relationships: Jianhua Zhang, None; Vivien J.Coulson-Thomas, None; Yong Yuan, None; Osamu Yamanaka,None; Hongshan Liu, None; Winston W. Kao, NoneSupport: NIH/NEI RO-1 EY011845, Research to Prevent Blindness,Ohio Lions Eye Research FoundationProgram Number: 2569 Poster Board Number: D0369Presentation Time: 2:45 PM - 4:30 PMIn Keratoconus are Epithelial and Stromal Changes Correlated?Colton Heinrich 1 , Andrew P. Kemp 1 , Jessica H. Mathew 1 , JohnGoosey 2, 1 , Jan P. Bergmanson 1 . 1 College of Optometry, Universityof Houston, Houston, TX; 2 Ophthalmology, Houston Eye Associates,Houston, TX.Purpose: The purpose of this study was to quantify histopathologicalchanges to anterior limiting lamina (ALL) and epithelial basementmembrane (BM) peripheral to Fleischer’s ring in keratoconic (Kc)corneas, to determine if a correlation exists between these changes,and to search peripheral stroma for histopathological signs ofprominent nerves.Methods: Nine surgically removed Kc corneal buttons and twocontrol corneas were preserved and processed for light andtransmission electron microscopy (TEM) using an establishedprotocol. Five digital pictures per cornea were obtained from bothALL and BM with the Tecnai G 12 twin TEM at 4200x and 16500xrespectively. Two measurements were taken per micrograph using amillimeter rule and adjusted to scale. Average values were calculatedand compared.Results: The average ALL thickness for Kc was 7.841µm(Range=5.68 - 10.22µm) and for control was 9.80µm (Range=9.70 -9.90µm). The average BM thickness was 0.4311µm (Range=0.19 -0.69µm) and was 0.17µm (Range=0.16 - 0.19µm) for Kc and controlrespectively. No correlation was found between the thickening of theBM and the thinning of the ALL (r=-0.2). Abnormal nerve fiberswith thickened basement membranes were found within the Kcperipheral stromal tissue.Conclusions: The thinned ALL and thickened BM supportedprevious reports of being characteristics in patients with Kc, not onlycentrally but also peripherally. However, the lack of correlationbetween the abnormalities of the ALL and BM provided evidencethat these pathological processes are independent of each other.Stromal nerve fibers observed in the stroma were abnormal and mayexplain the loss of corneal sensitivity noted in Kc patients but thesealterations appeared not to correlate well with their distinctprominence as seen clinically.Commercial Relationships: Colton Heinrich, None; Andrew P.Kemp, None; Jessica H. Mathew, None; John Goosey, None; JanP. Bergmanson, Contamac (F)Support: NEI/NIH Core Grant P30 EY07551; NEI/NIH TrainingGrant T35007088Program Number: 2570 Poster Board Number: D0370Presentation Time: 2:45 PM - 4:30 PMExpression of the neural stem cell marker Hes3 in the rodent andhuman ocular surfaceMatina Economopoulou 1 , Jimmy Masjkur 2 , Frederick Raiskup 1 , MikeKarl 3 , Richard H. Funk 4 , Triantafyllos Chavakis 2 , Lutz E. Pillunat 1 ,Andreas Androutsellis-Theotokis 2 . 1 Ophthalmology, University ClinicDresden, Dresden, Germany; 2 Department of Internal Medicine(MK3), University Clinic Dresden, Dresden, Germany; 3 Center forRegenerative Therapies Dresden, Dresden, Germany; 4 Department ofAnatomy, University Clinic dresden, Dresden, Germany.Purpose: Hairy and Enhancer of Split 3 (Hes3) is a recentlyestablished biomarker of neural stem cells in the fetal and adult brainof rodents and primates, including humans. Expression of Hes3persists during quiescence, allowing the detection of nonproliferatingstem cells and precursor cells. Hes3 also identifiesputative cancer stem cells in aggressive brain tumors, rendering it auseful biomarker of both normal and cancerous neural stem cells. Inthis work we address whether Hes3 can also be found on the ocularsurface.Methods: Adult mouse and human eye tissue was prepared forimmunohistochemical detection of Hes3 and other markers.Physiological human tissue was obtained from a <strong>Cornea</strong> bank andpterygium samples were obtained from pterygium excision surgeryafter patient consent.Results: The adult rodent and human eye, as well as pterygiumsamples, contain a population of cells expressing Hes3. In the humaneye, Hes3+ cells are found predominantly in the limbus where theyphysically associate with blood vessels.Conclusions: Hes3, a recent biomarker of neural stem cells in theadult brain and spinal cord, as well as in brain tumors, is alsoexpressed in the human limbus and in pterygium. Hes3+ cells in theeye also show similarities to those in the brain, in that they maintaintight physical associations with blood vessels. These results suggestthat limbal Hes3+ cells may have precursor properties, and that acommon mechanism may regulate Hes3+ cells in the brain and theeye.Commercial Relationships: Matina Economopoulou, None;Jimmy Masjkur, None; Frederick Raiskup, None; Mike Karl,None; Richard H. Funk, None; Triantafyllos Chavakis, None;Lutz E. Pillunat, None; Andreas Androutsellis-Theotokis, NoneSupport: Else Kroener-Fresenius-Stiftung and the Centre forRegenerative Therapies Dresden (CRTD) to AATProgram Number: 2571 Poster Board Number: D0371Presentation Time: 2:45 PM - 4:30 PM<strong>Cornea</strong>l condition and anterior segment pathology in patientswith bullous keratopathyElena Adjievska, Petja I. Vassileva, Nikolay Surchev, TatyanaHergeldzhieva-Fileva. University Eye Hospital "Prof. Pashev", Sofia,Bulgaria.©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35:
ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37:
ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39:
ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41:
ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43:
ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45:
ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47:
ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49:
ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51:
ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53:
ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55:
ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57:
ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59:
ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61:
ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63:
ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65:
ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67:
ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69:
ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71:
ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73:
ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75:
ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77:
ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79:
ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81:
ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83:
ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85:
ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87:
ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89:
ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91:
ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95:
ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97:
ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99:
ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101:
ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103:
ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105:
ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107:
ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109:
ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111:
ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113:
ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115:
ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117: ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119: ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121: ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123: ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125: ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127: ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129: ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131: ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133: ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135: ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137: ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139: ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141: ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143: ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145: ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147: ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149: ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151: ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153: ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155: ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157: ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159: ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161: ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163: ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165: ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169: ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171: ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173: ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175: ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177: ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179: ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181: ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183: ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185: ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187: ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189: ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191: ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193: ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195: ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197: ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199: ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201: ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203: ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205: ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207: ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209: ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211: ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213: ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215: ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217:
ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219:
ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221:
ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223:
ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225:
ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227:
ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229:
ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231:
ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233:
ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235:
ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237:
ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239:
ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241:
ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243:
ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245:
ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247:
ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249:
ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251:
ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253:
ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255:
ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257:
ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259:
ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261:
ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263:
ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265:
ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267:
ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269:
ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271:
ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273:
ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275:
ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277:
ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279:
ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281:
ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283:
ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285:
ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287:
ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289:
ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291:
ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293:
ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts